[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyslipidemias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyslipidemias":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,57,85,121,144,177,201,227,275,298,334,357,381,403,427,451,474,489,517,539,559,581,609,633,656],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":36,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100639438","uppsala-self-screening-of-cardiovascular-health-100639438",false,"NCT07614659","Uppsala Self-Screening of Cardiovascular Health","Uppsala Self-Screening of Cardiovascular Health: A Randomized Controlled Trial of Home-Based Multimodal Cardiovascular Screening Versus Usual Care in Middle-Aged and Older Adults","U-SCREEN","Inclusion Criteria:\n\n* Resident in Region Uppsala, Sweden\n* Turning 50, 55, 60, 65, 70 or 75 years during recruitment period\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Protected identity",true,"ALL","50 Years","75 Years",{"count":23,"type":24},45000,"ESTIMATED","INTERVENTIONAL",[27],"NA","U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.",[30,31,32,33,34,35],"Cardiovascular Diseases","Hypertension","Dyslipidemias","Diabetes Mellitus","Atrial Fibrillation","Chronic Kidney Disease",[37,38,39,40,41,42,43],"Population screening","Cardiovascular prevention","Home blood pressure monitoring","Dried blood spot","Digital health","Pragmatic trial","Register-based randomized controlled trial","RECRUITING","2026-06-26",{"date":47,"type":48},"2026-06-30","ACTUAL",{"date":50,"type":48},"2025-02-01",{"date":52,"type":24},"2037-12",{"name":54,"class":55},"Johan Sundström","OTHER",1,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":25,"phases":67,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":56},"100539177","randomized-controlled-trial-of-alert-based-computerized-decision-support-for-patients-with-peripheral-artery-disease-not-prescribed-lipid-lowering-therapy-100539177","NCT06300450","Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy","PAD-ALERT","Inclusion Criteria:\n\n* All patients ≥ 18 years old\n* Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology\n* Medical history entry, visit diagnosis, or problem list entry of PAD\n* Not prescribed LDL-C-lowering therapy\n\nExclusion Criteria:\n\n* Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded","18 Years",{"count":66,"type":24},400,[27],"This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.",[70,71,32],"Peripheral Artery Disease","Peripheral Vascular Diseases",[73,70,74,75],"Dyslipidemia","Peripheral Vascular Disease","Computerized Decision Support","2026-06-16",{"date":78,"type":48},"2026-06-17",{"date":80,"type":48},"2023-03-01",{"date":82,"type":24},"2026-12-30",{"name":84,"class":55},"Brigham and Women's Hospital",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":19,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":25,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100641936","nudging-preventive-screening-via-message-framing-and-bundling-100641936","NCT07644910","Nudging Preventive Screening Via Message Framing and Bundling","The Effect of Message Framing and Screening Bundling on Preventive Screening Engagement: A Randomized Field Experiment","Inclusion Criteria:\n\n* Has at least one pending cancer screening (breast, colorectal, cervical, or prostate) within the contact window, as determined by the medical institution\n* Aged 21 to 74 years\n* Has a valid phone number on file\n* Eligibility is determined operationally before randomization (ex-ante)\n\nExclusion Criteria:\n\n* Participants whose WhatsApp message was not successfully delivered, as reported by the third-party software used by the medical institution.","21 Years","74 Years",{"count":95,"type":24},235000,[27],"This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk\u002FImportance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening.\n\nIn both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the \"Arms and Intervention\" section (or counted for \"number of arms\").",[99,100,101,102,33,32],"Breast Neoplasms","Uterine Cervical Neoplasms","Colorectal Neoplasms","Prostatic Neoplasms",[104,105,106,107,108,109,110,111],"Behavioral science","randomized controlled trial","WhatsApp patient outreach","message framing","information avoidance","cancer screening","chronic disease testing","preventive care","NOT_YET_RECRUITING","2026-06-15",{"date":78,"type":48},{"date":116,"type":24},"2026-06-08",{"date":118,"type":24},"2026-12-08",{"name":120,"class":55},"University of Chile",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":25,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100643720","phase-1-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-mwx205-100643720","NCT07634510","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MWX205 Injection in Adult Participants With Dyslipidemia","Inclusion Criteria:\n\n1. Adult participants with dyslipidemia will be enrolled in this study.\n2. The absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.\n3. Participants must have fasting triglycerides greater than or equal to 150 mg\u002FdL (1.7 mmol\u002FL) and less than 500 mg\u002FdL (5.7 mmol\u002FL), and LDL-C greater than or equal to 70 mg\u002FdL (1.8 mmol\u002FL) at pre-screening and confirmation within 7 days before randomization.\n4. Have a body mass index within the range 18.5 to 40.0 kg\u002Fm2 (inclusive), with no plans to significantly alter diet or BMI over the course of study.\n5. Females of childbearing potential and males who are not surgically sterile (\\> 90 days since vasectomy with no viable sperm) will agree to use contraception from Screening until 6 months after the administration, OR females of non-reproductive potential\n\nExclusion Criteria:\n\n1. Positive pregnancy test or lactating female participant.\n2. Systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 40 or over 90 mmHg, HR less than 40 or over 100 bpm at screening.\n3. QTcF over 450 ms at screening.\n4. Consume more than 7 units for women or 14 units for men of alcohol per week within 8 weeks prior to screening (1 unit = 285 mL of beer 3.5%, 75 mL of wine 13.5%, or 25 mL of distilled alcohol 40%).\n5. Participants with established coronary artery disease, peripheral arterial disease, prior stroke, or other clinically significant atherosclerotic cardiovascular disease (such as stent placement or heart bypass, unstable angina or last known ejection fraction of \\\u003C50%).\n6. History of intolerance to SC injection or relevant abdominal scarring (surgical, burns, etc.), or any skin conditions, including infections or open wounds, or dermatitis at the injection site that could interfere with the evaluation of injection reaction.\n7. Have taken any prescription medications that are specifically indicated for lowering serum TGs (e.g., fibric acid derivatives, niacin, and omega-3 fatty acids \\[\\>1 g\u002Fday\\]) or medications that interfere with absorption of dietary cholesterol or fats (e.g., bile acid sequestrants, orlistat) within 2 months prior to screening.\n8. Have received treatment with any liver-targeted siRNA therapy or ASO (Antisense Oligonucleotide) within12 months prior to screening.\n9. Use of ANGPTL3 or PCSK9-inhibiting monoclonal antibodies within 90 days prior to screening.\n10. Use of systemic glucocorticoid therapy for more than 14 consecutive days in the past year, or any glucocorticoid therapy (excluding topical, intra-ocular, intra-articular, intranasal, or inhaled preparations) within 1 month before screening.","60 Years",{"count":130,"type":24},37,[132],"PHASE1","This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia).\n\nResearchers will check if a single dose of MWX205 is safe and how the body reacts to it. They will also measure how quickly the drug enters the bloodstream and how long it stays in the body, and compare it with a placebo (inactive treatment).\n\nThe study will help decide the right dose and understand how this medicine could be used in future treatments.\n\nThe main questions this study aims to answer are:\n\n1. Is MWX205 safe after a single dose?\n2. How does the body process MWX205?\n3. Does MWX205 show any effect on the body related to cholesterol levels?",[32],{"date":136,"type":48},"2026-06-10",{"date":138,"type":24},"2026-06-22",{"date":140,"type":24},"2027-11-08",{"name":142,"class":143},"Shanghai Minwei Biotechnology Co., Ltd","INDUSTRY",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":21,"enrollmentInfo":151,"targetDuration":4,"studyType":25,"phases":153,"briefSummary":154,"conditions":155,"keywords":165,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100630707","phase-1-a-safety-and-tolerability-trial-evaluating-ctx310-in-participants-with-refractory-dyslipidemias-100630707","NCT07491172","A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias","A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias","Key Inclusion Criteria:\n\n1. Age of ≥18 and ≤75 years at the time of signing the informed consent.\n2. Able to provide written informed consent.\n3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg\u002FdL - and LDL-C ≥70 mg\u002FdL in participants with ASCVD, or LDL-C ≥70 or 100mg\u002FdL in participants with or without ASCVD respectively, or TG ≥500 mg\u002FdL.\n4. Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening\n5. Female participants must be postmenopausal or surgically sterile.\n6. All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.\n\nExclusion Criteria:\n\n1. Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.\n2. Evidence of liver disease, defined as but not limited to:\n\n   LFTS \\>2 × upper limit of normal (ULN), or total bilirubin \\>2 × ULN, or INR \\>1.5 × ULN, or liver stiffness measured by liver elastography\n3. Abnormal or compromised function of kidney, heart, blood or liver.\n4. Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.\n5. Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).\n6. Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.\n7. Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).\n8. Women of childbearing potential.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.\n\nNote: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.",{"count":152,"type":24},90,[132],"This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.",[156,157,32,158,159,160,161,162,163,164],"Cardiovascular","Metabolic Disease","Lipid Disorder","Hypertriglyceridemia","Heterozygous Familial Hypercholesterolemia (HeFH)","Homozygous Familial Hypercholesterolemia (HoFH)","Severe Hypertriglyceridemia (sHTG)","Mixed Hyperlipemia","Hypercholesterolaemia",[166],"Refractory Dyslipidemias","2026-05-19",{"date":169,"type":48},"2026-05-22",{"date":171,"type":48},"2024-06-21",{"date":173,"type":24},"2028-06",{"name":175,"class":143},"CRISPR Therapeutics AG",18,{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":25,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":56},"100530171","effects-of-nattokinase-on-inflammation-and-cardiovascular-risk-markers-in-patients-with-dyslipidemia-100530171","NCT06183307","Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia","Inclusion Criteria:\n\n* Both sexes;\n* Over 18 years of age;\n* Isolated increase in LDL-c (LDL-c ≥ 160 mg\u002FdL);\n* Isolated increase in triglycerides (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* increased LDL-c (LDL-c ≥ 160 mg\u002FdL)\n* TG (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* Reduction in HDL-c (men \\\u003C 40 mg\u002FdL and women \\\u003C 50 mg\u002FdL) alone or in association with an increase in LDL-c or TG. If TG ≥ 400 mg\u002FdL.\n* Individuals who are already using lipid-lowering therapy (statins or non-statins) will also be included.\n\nExclusion Criteria:\n\n* Participants with autoimmune and infectious diseases, diabetes, cancer and AIDS;\n* Pregnant women;\n* Participants using catabolic drugs or antibiotics\n* Participants on anticoagulant medication\n* Participants using antioxidant vitamin supplements, prebiotic, probiotic or synbiotic and who are allergic to corn or soy starch.",{"count":184,"type":24},48,[27],"The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.",[30,32,188],"Inflammation",[190,30,188,191],"nattokinase","fibrinogen","2026-05-12",{"date":194,"type":48},"2026-05-14",{"date":196,"type":48},"2024-08-03",{"date":198,"type":24},"2026-12-20",{"name":200,"class":55},"Universidade Federal Fluminense",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":19,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":25,"phases":212,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":56},"100467336","phase-4-atmeg-atorvastatin-and-omega-3-combination-and-carotid-atherosclerosis-in-patients-with-type-2-diabetes-and-combined-dyslipidemia-100467336","NCT05365438","Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia under moderate-intensity statin: triglyceride ≥200 mg\u002FdL, HDL-cholesterol ≤50 mg\u002FdL, LDL-cholesterol ≥100 mg\u002FdL\n\n  * moderate-intensity statin: atorvastatin 10-20mg, rosuvastatin 5mg, simvastatin 20-40mg, pravastatin 40-80mg, lovastatin 40mg, fluvastatin XL 80mg, fluvastatin 40mg bid, pitavastatin 2-4mg\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Asymptomatic patients without history of angina, myocardial infarction, or cerebral infarction\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension: SBP \\>180 mmHg or DBP \\>110 mmHg\n* Severe renal dysfunction: eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n* AST\u002FALT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Usage of dyslipidemia therapy other than statin","20 Years","80 Years",{"count":211,"type":24},105,[213],"PHASE4","This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.",[32,216,217],"Atherosclerosis","Diabetes Mellitus, Type 2","2026-05-02",{"date":220,"type":48},"2026-05-05",{"date":222,"type":48},"2022-10-01",{"date":224,"type":24},"2026-12-31",{"name":226,"class":55},"Seoul National University Bundang Hospital",{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":18,"sex":19,"minAge":235,"maxAge":21,"enrollmentInfo":236,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":239,"conditions":240,"keywords":253,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":56},"100346729","psychosocial-environmental-and-chronic-disease-trends-in-puerto-rico-100346729","NCT03794531","Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico","Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic Disease Trends","PROSPECT","Inclusion Criteria:\n\n1. Age 30-75 years old at the time of enrollment\n2. Non-institutionalized\n3. Living in PR at the time of the first interview and the year before and not planning to move from the island within 3 years\n4. Able to answer questions without assistance\n5. Living in a stable dwelling\n\nExclusion Criteria:","30 Years",{"count":237,"type":24},2500,"OBSERVATIONAL","The overall goal is to identify trends and longitudinal associations in psychosocial, food-related, and cardiometabolic risk factors that can guide public health priorities and future research needs aimed at reducing cardiovascular-related disparities in Puerto Rico. To this end, investigators will establish 'PROSPECT: Puerto Rico Observational Study of Psychosocial, Environmental, and Chronic disease Trends', an island-wide, longitudinal population cohort of 2,500 adults (30-75 years) in PR recruited with a community-wide sampling strategy, and assessed in a network of several partner clinics across the island. The study will collect comprehensive data on multiple psychosocial, dietary, and food-related factors, CVD biological markers, and medical record data, with follow-up at 2-years, and will assess variations by urban-rural area and by timing before-after Maria.",[241,242,31,243,32,244,30,245,188,246,247,248,249,250,251,252],"Heart Diseases","Type2 Diabetes","Obesity","Metabolic Syndrome","Chronic Disease","Psychological Stress","Physiological Stress","Depressive Symptoms","Coping Behavior","Diet Habit","Lifestyle","Food Insecurity",[254,255,256,257,258,259,260,261,262,263,264,265,266],"Hispanics\u002FLatinos","Minority health","Puerto Rico","Cardiovascular disease","Cardiometabolic health","Chronic disease risk factors","Disaster research","Caribbean and Latin America","Population health","Prospective study","Allostatic load","Food insecurity","Longitudinal study","2026-04-30",{"date":220,"type":48},{"date":270,"type":48},"2019-03-01",{"date":272,"type":24},"2029-04-30",{"name":274,"class":55},"Harvard School of Public Health (HSPH)",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":18,"sex":19,"minAge":64,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":25,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100635347","phase-1-safety-pk-and-pd-of-bsa204-in-chinese-adults-with-borderline-elevated-lipoproteina-100635347","NCT07551505","Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of BSA204 Injection in Chinese Adults With Borderline Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Body mass index (BMI) 18 to 30 kg\u002Fm2\n* Fasting triglycerides (TG) ≤ 4.5 mmol\u002FL\n* Borderline elevated fasting lipoprotein(a) \\[Lp(a)\\] levels as defined in the protocol\n* Fasting low-density lipoprotein cholesterol (LDL-C) within the range specified for the assigned dose cohort\n* o clinically significant abnormalities of hepatic or renal function\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History or presence of significant medical conditions\n* Abnormal ECG findings, including a prolonged QTcF interval (\\> 450 msec for males or \\> 470 msec for females)\n* Prior treatment with small interfering RNA (siRNA) or antisense oligonucleotides within 12 months, or recent use of specific lipid-lowering therapies\n* Known allergy to any component of the study drug","55 Years",{"count":284,"type":24},40,[132],"The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) \\[Lp(a)\\].",[32],"2026-04-23",{"date":290,"type":48},"2026-04-28",{"date":292,"type":24},"2026-04-20",{"date":294,"type":24},"2027-12-31",{"name":296,"class":143},"Bisirna Therapeutics (Suzhou) Co., Ltd.",2,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":309,"conditions":310,"keywords":319,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":332,"locationsCount":56},"100506981","prevalence-incidence-and-risk-signature-of-chronic-kidney-disease-in-sub-saharan-africa-100506981","NCT05881447","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in a Primary Care Setting in Semirural Sub-Saharan Africa","RenalTWO","Inclusion Criteria:\n\nall adult patients (≥18 years) attending the outpatients department of the Bagamoyo district hospital (BDH) or the associated Fukayosi and Yombo dispensary\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* not living in the BDH catchment area\n* not of African decent\n* not willing to come back for follow-up visits","99 Years",{"count":308,"type":24},1200,"Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA). Key shortcomings of available data on CKD in SSA are as follows: (i) Available data are based on single measurements and, therefore, cannot distinguish between harmless transient deterioration in kidney function and chronic kidney damage; (ii) Accurate information regarding renal protein loss, an important and early marker of kidney disease, is lacking; (iii) Cardiovascular risk factors for CKD, such as obesity, hypertension and diabetes, are often not searched for. Likewise non-classic potential risk factors, such as endemic infectious diseases, socioeconomic status and lifestyle have not been consistently recorded; (iv) Information to interrogate linked interaction over time between risk factors and development of CKD is unavailable. With this project, situated in a region representative of semi-rural SSA, we aim to fill this knowledge gap and (i) establish guideline conform prevalence data of CKD and its major cardiovascular risk factors, as well as (ii) prospectively define the incidence of cardiovascular- and non-classic risk factors of CKD. The data from (i) and (ii) is used to develop predictive models. A prospective cohort of 1200 individuals in a primary care facility will serve as study population. The population is representing a society in transition from rural to more urban lifestyle. In the pilot study, participants will be followed for one years and undergo the clinical and biomedical testing required to capture CKD and its classic and non-classic risk factors over time.",[311,312,313,243,30,314,315,316,317,318,32],"Chronic Kidney Diseases","Type 2 Diabetes Mellitus","Arterial Hypertension","HIV Infections","Anemia","Underweight","Infections","Albuminuria",[320,321,257,315,322,323,324,325,326],"CKD","Risk factors","Point of care diagnostics","Albumin creatinine ration (ACR)","Estimated glomerular filtration rate (eGFR)","Kidney Disease: Improving Global Outcomes (KDIGO)","HbA1c",{"date":328,"type":48},"2026-04-29",{"date":330,"type":48},"2023-06-21",{"date":224,"type":24},{"name":333,"class":55},"Swiss Tropical & Public Health Institute",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":19,"minAge":342,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":25,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":56},"100634748","group-medical-visits-for-patients-with-dyslipidemia-100634748","NCT07543718","Group Medical Visits for Patients With Dyslipidemia","Improving Care Through Group Medical Visits for Patients With Dyslipidemia","PARTAGE-D","Inclusion Criteria:\n\n* Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol\u002FL or non-HDL-C ≥ 4.2 mmol\u002FL or ApoB ≥ 1.05 g\u002FL\n\nExclusion Criteria:\n\n* Patients unable to participate in GMV sessions or to provide informed consent\n\n  * Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months)\n  * A diagnosis of terminal illness or a life expectancy of less than 12 months","40 Years",{"count":344,"type":24},288,[27],"Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.",[32],"2026-04-14",{"date":350,"type":48},"2026-04-22",{"date":352,"type":24},"2026-04",{"date":354,"type":24},"2030-12",{"name":356,"class":55},"Université de Sherbrooke",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":18,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":56},"100411213","the-bialystok-bariatric-surgery-study-100411213","NCT04634591","The Bialystok Bariatric Surgery Study","BBSS","Inclusion Criteria:\n\n* BMI ≥ 40 kg\u002Fm2, or BMI ≥ 35 and at least one or more obesity-related co-morbidities such as type 2 diabetes (T2D), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease.\n* Inability to achieve a healthy weight loss sustained for a period of time with prior weight loss efforts\n* Patient consent for participation in research project\n* Willingness in participation in follow-up visits\n\nExclusion Criteria:\n\n* substance abuse,\n* uncontrolled psychiatric illness\n* expected lack of compliance\n* advanced-stage cancer\n\nNon-obese control group:\n\n* BMI \\\u003C30",{"count":365,"type":24},1000,"The Bialystok Bariatric Surgery Study (BBSS) is a prospective observational cohort study of patients undergoing bariatric surgery at the First Clinical Department of General and Endocrine Surgery at the Medical University of Bialystok. The BBSS consists of a battery of baseline tests established one month prior to the surgery and repeated at one, three, six, twelve and twenty four-month follow-up clinical visits.",[243,33,244,32,368],"PreDiabetes",[370,371,372,373],"bariatric surgery","diabetes treatment","prediabetes treatment","metabolic surgery","2026-04-09",{"date":348,"type":48},{"date":377,"type":48},"2015-09-10",{"date":224,"type":24},{"name":380,"class":55},"Medical University of Bialystok",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":21,"enrollmentInfo":389,"targetDuration":4,"studyType":25,"phases":391,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":56},"100554219","phase-2-impact-of-obicetrapib-and-obicetrapib-plus-repatha-on-lpa-levels-100554219","NCT06496243","Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels","A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study","VINCENT","Inclusion Criteria:\n\n* Lp(a): \\>=50 mg\u002FdL (\\>=125 nmol\u002FL) for cohort 1 (FILLED) and Lp(a) \\>= 20 mg\u002FdL (\\>= 50 nmol\u002FL) to \\\u003C50 mg\u002FdL (\\\u003C 125 nmol\u002FL) for cohort 2\n* LDL-C \\>70 mg\u002FdL\n* TG \\\u003C 400mg\u002FdL (\\\u003C4.52 mmol\u002FL)\n\nExclusion Criteria:\n\n* HbA1c\\>=10 or FPG \\>=270 mg\u002FdL\n* CV events within 3 months of screen",{"count":390,"type":24},69,[392],"PHASE2","The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib\u002Fevolocumab\n\nPatients will:\n\nHave baseline Lp(a) tested at randomization Take 10mg\u002FdL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg\u002FdL obicetrapib daily\u002Fevolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16",[32],"2026-04-06",{"date":374,"type":48},{"date":398,"type":48},"2024-12-02",{"date":400,"type":24},"2027-02",{"name":402,"class":143},"NewAmsterdam Pharma",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":19,"minAge":411,"maxAge":4,"enrollmentInfo":412,"targetDuration":414,"studyType":238,"phases":4,"briefSummary":415,"conditions":416,"keywords":417,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":56},"100633229","efficacy-and-safety-of-pitavastatinezetimibe-in-dyslipidemia-patients-with-metabolic-syndrome-an-observational-study-100633229","NCT07523971","Efficacy and Safety of Pitavastatin\u002FEzetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study","A Multi-center, Open-label, Observational Study to Evaluate the Efficacy and Safety of Pitavastatin\u002FEzetimibe Tablets in Patients With Dyslipidemia Who Also Have Metabolic Syndrome","PIVOT","Inclusion Criteria:\n\n1. Age 19 years old at the time of written informed consent\n2. Subjects diagnosed with dyslipidemia and metabolic syndrome\n3. Subjects who had no treatment history with lipid regulators within 4 weeks prior to Visit1 or who had insufficient therapeutic effects from 8 weeks of treatment with lipid regulators using the same dosage and administration\n4. Subjects who meet the following LDL-C levels according to the classification of cardiovascular disease risk groups\\* at Visit 1 or who are planned to be treated with Pitavastatin\u002FEzetimibe Tablets based on the judgment of the investigator\n5. Subjects who voluntarily sign the informed consent form for study participation\n\nExclusion Criteria:\n\n1. Individuals for whom Pitavastatin\u002FEzetimibe Tablets is contraindicated as specified in the label's Precautions for Use\n2. Individuals who were treated with other investigational products (IP) or investigational devices within 4 weeks prior to participation in the present study or who are expected to have such treatment during the present study\n3. Individuals who are considered to have difficulty participating in the study for other reasons based on the judgment of the investigator","19 Years",{"count":413,"type":24},10000,"1 Year","The purpose of this study is to evaluate the efficacy and safety of Pitavastatin\u002FEzetimibe tablets (a fixed-dose combination of Pitavastatin and Ezetimibe) in patients with dyslipidemia who also have metabolic syndrome in a real-world clinical setting.\n\nAs this is an observational study, participants will be treated according to the investigator's medical judgment and routine clinical practice. The study aims to observe the changes in low-density lipoprotein cholesterol (LDL-C) levels from baseline to 24 weeks and 48 weeks of treatment. Safety will also be assessed by monitoring any adverse events occurring during the 48-week observation period.",[32],[244],"2026-04-05",{"date":420,"type":48},"2026-04-13",{"date":422,"type":48},"2025-06-25",{"date":424,"type":24},"2027-06",{"name":426,"class":143},"JW Pharmaceutical",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":209,"enrollmentInfo":434,"targetDuration":4,"studyType":25,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":450},"100577369","phase-2-phase-2-trial-evaluating-the-efficacy-and-safety-of-rbd5044-in-patients-with-mixed-dyslipidemia-100577369","NCT06797401","Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia","Inclusion Criteria:\n\n* Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.\n* Male or female participants, aged 18 to 80 years inclusive.\n* Fasting TG level of ≥ 150 mg\u002FdL (≥ 1.69 mmol\u002FL) and \\\u003C499 mg\u002FdL (5.61 mmol\u002FL).\n* Fasting levels at screening of non-HDL-C ≥ 100 mg\u002FdL (2.59 mmol\u002FL), or low-density lipoprotein cholesterol (LDL-C) ≥70 mg\u002FdL (1.8 mmol\u002FL) after at least 4 weeks of stable diet and stable optimal statin therapy (+ or - ezetimibe) if indicated.\n* Body mass index between 18 and 40 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical trial and\u002For put the participant at significant risk (according to the investigator's judgment) if he\u002Fshe participates in the clinical trial.\n* Uncontrolled hypertension (blood pressure \\>160\u002F100 mmHg at screening). (If untreated, participant may be re-screened once hypertension is treated and controlled).\n* Active or history of serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or severe depression, which require current pharmacological intervention. Participants with a history of severe depression who are no longer on medication.\n* Any of the following laboratory values at screening:\n\nHepatic: ALT or AST \\>2× ULN at screening, eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 (using the Modification of Diet in Renal Disease \\[MDRD\\] equation) at Screening, HbA1c \\>9.0% (or \\>75 mmol\u002Fmol International Federation of Clinical Chemistry \\[IFCC\\] units) at screening.\n\n* Patients with a diagnosis of HBV, HCV or HIV at screening.",{"count":435,"type":24},120,[392],"The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are:\n\nDoes drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia.\n\nParticipants will:\n\nReceive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.",[32],[440],"Mixed dyslipidemia","2026-03-10",{"date":443,"type":48},"2026-03-12",{"date":445,"type":48},"2025-01-28",{"date":447,"type":24},"2026-09-30",{"name":449,"class":143},"Ribocure Pharmaceuticals AB",4,{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":18,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":25,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":297},"100556557","ai-pono-cooking-demonstrations-100556557","NCT06526650","'Ai Pono Cooking Demonstrations","The PILI 'Āina Project","Inclusion Criteria:\n\n* Age 18+ (looking for older adults)\n* Native Hawaiian resident in a participating homestead\n* Overweight or obese (BMI ≥ 25 kg\u002Fm\\^2)\n* Prior diagnosis of type 2 diabetes or pre-diabetes, hypertension, and\u002For dyslipidemia (LDL cholesterol ≥ 130 mg\u002FdL)\n* Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week\n* Willing and able to participate in all aspects of the individual and household-level intervention\n* Fluent in written and spoken English\n\nExclusion Criteria:\n\n* No children\n* Pregnancy\n* Serious illness such as cancer or chronic pain that may contraindicate full participation",{"count":459,"type":24},1780,[27],"Native Hawaiians' traditional lifestyles and diets ensured the mutual health and well-being of the land and its inhabitants, which stand in stark contrast to the disproportionately high prevalence of diet-related, cardiometabolic diseases they experience today. In this project, the investigators will adapt and test an evidence-based multilevel intervention entitled PILI 'Āina to improve the self-management of prevalent cardiometabolic diseases and reduce risk factors for developing new diet-related illnesses and implement and evaluate the impact and sustainability of community-wide cooking demonstrations. The objectives of this project are to optimize the effectiveness and sustainability of PILI 'Āina, improve diet quality, cardiometabolic markers, promote traditional Native Hawaiian diets, and improve social cohesion.",[463,31,32,464],"Type 2 Diabetes","Overweight and Obesity","2026-03-02",{"date":467,"type":48},"2026-03-04",{"date":469,"type":48},"2025-02-12",{"date":471,"type":24},"2028-08",{"name":473,"class":55},"University of Hawaii",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":456,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":25,"phases":482,"briefSummary":461,"conditions":483,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":486,"leadSponsor":488,"locationsCount":297},"100556528","pili-ina-household-100556528","NCT06526273","PILI 'Āina Household","Inclusion Criteria:\n\n* Age 18+ (looking for older adults)\n* Native Hawaiian resident in a participating homestead\n* Overweight or obese (BMI ≥ 25 kg\u002Fm\\^2)\n* Prior diagnosis of T2D or pre-diabetes, hypertension, and\u002For dyslipidemia (LDL cholesterol ≥ 130 mg\u002FdL)\n* Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week\n* Willing and able to participate in all aspects of the individual and household-level intervention\n* Fluent in written and spoken English\n\nExclusion Criteria:\n\n* No children\n* Pregnancy\n* Serious illness such as cancer or chronic pain that may contraindicate full participation",{"count":481,"type":24},210,[27],[463,31,32,464],{"date":467,"type":48},{"date":469,"type":48},{"date":487,"type":24},"2029-02-26",{"name":473,"class":55},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":18,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":498,"conditions":499,"keywords":503,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":56},"100616646","taining-golden-lake-comprehensive-chronic-disease-management-initiative-100616646","NCT07308314","Taining Golden Lake Comprehensive Chronic Disease Management Initiative","TAIGOLD-CDM","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* Resident of Taining County for ≥6 months and expected to remain in the county for at least the next 3 years.\n* Full civil capacity and able to understand study procedures.\n* Willing to voluntarily participate and provide written informed consent.\n* Able to complete baseline survey and follow-up visits.\n\nExclusion Criteria:\n\n* Refusal to sign informed consent.\n* Severe psychiatric disorders or cognitive impairment preventing participation.\n* End-stage disease with expected survival \\\u003C1 year.\n* Long-term migrants (≥6 months per year outside the county), unable to guarantee follow-up.\n* Participation in other clinical studies that may interfere with this research.",{"count":497,"type":24},20000,"This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.",[245,500,31,33,32,501,502],"Chronic Disease Management","Frailty","Sarcopenia",[500,504,31,33,73,505,501,502,506,507],"Prospective Cohort","Cardiovascular Disease","Aging","Healthy Aging","2025-12-15",{"date":510,"type":48},"2025-12-29",{"date":512,"type":48},"2025-08-01",{"date":514,"type":24},"2028-07-01",{"name":516,"class":55},"First Affiliated Hospital of Fujian Medical University",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":18,"sex":19,"minAge":64,"maxAge":524,"enrollmentInfo":525,"targetDuration":4,"studyType":25,"phases":527,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":56},"100493112","early-phase-1-evaluation-of-milk-polar-lipids-in-dyslipidemic-adults-with-abdominal-obesity-100493112","NCT05700916","Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity","Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity","Inclusion Criteria:\n\n* LDL-C ≥ 130 mg\u002FdL\n* Waist circumference ≥ 88 cm for women, ≥ 102 cm for men\n* Aged 18 to 70 years\n\nExclusion Criteria:\n\n* Renal disease\n* Liver disease\n* Diabetes\n* Heart disease\n* Stroke\n* Cancer\n* Eating disorders\n* Thyroid disease\n* Gut-associated pathologies\n* Autoimmune diseases\n* Chronic inflammatory diseases\n* Scleroderma\n* Gallbladder disease\n* Blood clotting disorders\n* Intravenous drug use\n* Fasting plasma\u002Fserum triglycerides \\>500 mg\u002FdL\n* Fasting plasma\u002Fserum glucose \\>126 mg\u002Fd\n* Weight changes \\>10% over last 4 weeks\n* Oral antibiotics use up to 1 month prior to and during study\n* Allergy or intolerance to milk products\n* Taking lipid-lowering medications (e.g., statins, fibrates)\n* Taking anti-inflammatory medications (e.g., corticosteroids)\n* Taking medications which primarily affect blood clotting (e.g., warfarin).","70 Years",{"count":526,"type":24},130,[528],"EARLY_PHASE1","The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.",[32,243],{"date":532,"type":48},"2025-12-22",{"date":534,"type":48},"2023-10-20",{"date":536,"type":24},"2026-06",{"name":538,"class":55},"University of Connecticut",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":19,"minAge":342,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":25,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":558},"100476783","phase-2-cholesterol-and-inflammation-lowering-via-bempedoic-acid-an-acl-inhibiting-regimen-in-hiv-trial-clear-hiv-trial-100476783","NCT05488431","Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)","Inclusion Criteria:\n\n* Documented HIV infection\n* On continuous antiretroviral therapy and virologically suppressed HIV infection for ≥12 weeks prior to study entry\n* CD4 T-cell count ≥ 200 cells\u002Fmm3\n* Male or female between the ages ≥ 40 years of age\n* LDL-C ≥ 50 mg\u002FdL\n* Documented cardiovascular disease as defined by: 1. Prior myocardial infarction, 2. Prior cerebrovascular disease, 3. Prior peripheral arterial disease, 4. History of percutaneous coronary intervention, 5. History of coronary artery bypass graft OR 6. Angiographic evidence of \\>50% stenosis in at least one coronary artery\\] OR 1 CVD risk factor (T2DM, current smoking, hypertension, dyslipidemia, hsCRP≥2mg\u002FL, family history)\n* TBR of \\>1.6 of the MDS of the carotid\u002Faorta at baseline. This baseline arterial TBR cutoff excludes the rare individual that lacks appreciable arterial inflammation. It is notable that while 5-10% of uninfected individuals will have lower TBRs, it is rare that an HIV infected individual will fall below this range.\n* Female subjects must either be of non-childbearing potential (defined as post-menopausal or amenorrhea \\> 12 months) or agree to use two forms of contraception (one hormonal and one barrier) throughout the study and for at least one month following study completion and have a negative pregnancy test at screening and prior to the first dose of drug.\n* Males must use at least one method of contraception throughout the study.\n\nExclusion Criteria:\n\n* Pregnant\u002Fnursing women (as there is no data on bempedoic acid in this setting)\n* Diabetes requiring insulin (as insulin treatment alters the uptake of 18FDG)\n* Uncontrolled HTN as defined by baseline blood pressure reading of ≥160 mmHg systolic OR ≥100 mmHg diastolic (exclusion criteria in other studies with BA)\n* AST\u002FALT or alkaline phosphatase \\>2x ULN\n* Triglycerides \\>500 mg\u002FdL at screening\n* Cancer within the last 5 years with exception of squamous cell carcinoma and basal cell carcinoma\n* Individuals on simvastatin \\>20mg or pravastatin \\>40mg. All other dosages and statins will be permitted with close monitoring for myopathies including assessment of CK levels\n* Nephrotic syndrome or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Cytopenias which include 1) WBC \\\u003C3.5 x103\u002FuL 2) Platelet \\\u003C120 x103\u002FuL 3) ANC \\\u003C1.5 x103\u002FuL, and absolute lymphocytes \\\u003C0.8 x 103\u002FuL\n* Anemia as fined by Hgb \\\u003C10 g\u002FdL\n* Acute systemic infection within 30 days",{"count":546,"type":24},121,[392],"This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET\u002FCT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.",[32,30,314,216],"2025-12-11",{"date":552,"type":48},"2025-12-17",{"date":80,"type":48},{"date":555,"type":24},"2028-03-01",{"name":557,"class":55},"Priscilla Hsue, MD",3,{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":297},"100545956","lipid-testing-after-myocardial-infarction-at-the-montreal-heart-institute-100545956","NCT06388668","Lipid Testing After Myocardial Infarction at the Montreal Heart Institute","Timing of Lipid Testing During Hospitalization for MI and Subsequent Management of Dyslipidemia An Observational Study to Reduce the Care Gaps in Dyslipidemia in Canada","Inclusion Criteria:\n\n* Adult patients ≥18 years old\n* Hospitalized at the Cardiac Care Unit for Myocardial Infarction (either NSTEMI or STEMI)\n* Lipid panel performed on day 0 of admission\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* None",{"count":567,"type":24},100,"Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization.\n\nIt will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute.\n\nEvery patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission.\n\nThereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.",[32,570,571],"Lipid Testing","Myocardial Infarction","2025-12-02",{"date":574,"type":48},"2025-12-03",{"date":576,"type":48},"2024-06-01",{"date":578,"type":24},"2026-05",{"name":580,"class":55},"Montreal Heart Institute",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":18,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":558},"100545316","military-health-and-nutrition-examination-study-100545316","NCT06380322","Military Health and Nutrition Examination Study","Stand Ready: Military Health and Nutrition Examination Study","MHANES","Inclusion Criteria:\n\n* U.S. Army Soldiers ≥ 18 years old\n* Willing to have biological samples stored for future use\n* Willing to have data linked to the Soldier Performance, Health, and Readiness (SPHERE) database\n\nExclusion Criteria:\n\n* Soldiers under the age of 18 years\n* Soldiers with an inability to understand verbal or written instructions or testing materials in English\n* Soldiers relocating or getting out of the Army in the next 30 days\n* Pregnant females\n* Soldiers currently in Basic Training (BCT) and\u002For One-Station Unit Training (OSUT)",{"count":590,"type":24},650,"The Military Health and Nutrition Examination Study (MHANES) is a Department of Defense funded study conducted by Pennington Biomedical Research Center and the US Army Research Institute of Environmental Medicine. This cross-sectional study will assess, in a large, diverse sample of Army Service Members (n=600), food and supplement intake, cardiovascular health, body composition, biomarkers of nutritional status, measures of health status, injury prevalence, mental wellbeing, gut microbiome composition, and physical performance outcomes. The proposed study is modeled after the National Health and Nutrition Examination Survey (NHANES) and customized for the Army population.",[31,463,32,30],[594,595,596,597,598,599],"Diet Quality","Healthy Eating Index","Body Composition","Dietary Supplements","Gut Microbiome","Army Combat Fitness Test","2025-11-10",{"date":602,"type":48},"2025-11-12",{"date":604,"type":48},"2024-08-24",{"date":606,"type":24},"2026-12-01",{"name":608,"class":55},"Pennington Biomedical Research Center",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":19,"minAge":92,"maxAge":616,"enrollmentInfo":617,"targetDuration":619,"studyType":238,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":56},"100439338","gut-microbiota-in-metabolic-surgery-100439338","NCT05000996","Gut Microbiota in Metabolic Surgery","The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study","Inclusion Criteria:\n\n* Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center\n* Have a history of type 2 diabetes, hypertension, or dyslipidemia\n* Be able and willing to provide personal information and biological samples needed for the study\n\nExclusion Criteria:\n\n* Prior gastric operations\n* A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis\n* Chemotherapy or radiotherapy for cancer within 2 years\n* Current inflammatory bowel disease or celiac disease\n* Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months","65 Years",{"count":618,"type":24},300,"10 Years","Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and\u002For tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.",[622,30,463,32,31,623],"Bariatric Surgery Candidate","Morbid Obesity","2025-11-02",{"date":626,"type":48},"2025-11-04",{"date":628,"type":48},"2021-08-19",{"date":630,"type":24},"2035-01-01",{"name":632,"class":55},"Vanderbilt University Medical Center",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":640,"targetDuration":641,"studyType":238,"phases":4,"briefSummary":642,"conditions":643,"keywords":644,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":56},"100488779","retinal-vascular-manifestations-in-patients-with-common-internal-diseases-on-octa-tomography-angiography-100488779","NCT05644548","Retinal Vascular Manifestations in Patients With Common Internal Diseases on OCTA Tomography Angiography","Retinal Vascular Manifestations in Patients With Common Internal Diseases on Optical Coherence Tomography Angiography","Inclusion Criteria:\n\n* Patients with hypertension\n* Or patients with diabetes\n* Or patients with dyslipidemia\n* Agree to participate in this study\n\nExclusion Criteria:\n\n* Patients with malignant tumors\n* Patients with autoimmune diseases\n* Patients with immunodeficiency disease\n* Disagree to participate in this study",{"count":618,"type":24},"5 Years","Hypertension, diabetes mellitus, and dyslipidemia are common internal diseases, and all diseases are atherosclerosis risk factors. Previous studies applied color fundus photography to analyze retinal vascular changes (including exudation, hemorrhage, neovascularization, etc.) in patients with hypertension or diabetes, but the examination results could not be quantified.\n\nThis study intends to apply optical coherence tomography angiography (OCTA) to examine retinal vessels. This method has the following advantages: 1) It can quantify vascular changes, and 2) It is noninvasive and reproducible for patients' follow-up.\n\nThis study was designed to investigate retinal vascular changes in patients with hypertension, diabetes, and dyslipidemia on OCTA. We will collect the patients' general information (gender, age), comorbidities, medications, blood lipids, blood glucose, carotid ultrasound, ankle-brachial index, ambulatory blood pressure monitoring, color fundus photography, and OCTA results. We will follow up with the patients for five years and conduct the mentioned examinations once a year. We will also investigate the correlation between systemic atherosclerosis (such as coronary artery stenosis, and carotid artery stenosis) and retinal vasculopathy in patients with these diseases.",[31,33,32],[645,31,646,32],"OCTA","Diabetes","2025-09-20",{"date":649,"type":48},"2025-09-25",{"date":651,"type":48},"2022-03-01",{"date":653,"type":24},"2028-12-31",{"name":655,"class":55},"Beijing Tongren Hospital",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":19,"minAge":64,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":25,"phases":666,"briefSummary":667,"conditions":668,"keywords":670,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":56},"100515235","effects-of-a-digital-health-application-lipodia-on-ldl-cholesterol-levels-100515235","NCT05988866","Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels","Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels in Individuals With LDL-cholesterol Levels Above Recommended Targets for Reducing Cardiovascular Risk: Randomized Controlled Trial","DIGICHOL","Inclusion criteria\n\n* Age ≥ 18\n* Diagnosis of hypercholesterolemia (ICD-10 E78.0, E78.2, E78.4, E78.5, E78.8, E78.9) confirmed by a laboratory test and physician diagnosis\n* LDL-C levels above risk-adapted target\n* TG levels \\\u003C 400 mg\u002FdL\n* Stability of potential drug treatment during the last 4 weeks\n* Stability of potential hormonal treatment during the last 6 months\n* Patient was made aware of lifestyle measures by GP or specialist\n* Consent to participation\n* Sufficient knowledge of the German language\n\nExclusion criteria\n\n* Homozygous Familial Hypercholesterolemia (FH), given that it is a genetic condition which is relatively unresponsive to lifestyle changes\n* Hyperlipidemia type III, given that it is a genetic condition which is relatively unresponsive to lifestyle changes\n* Patients receiving plasmapheresis\n* Lp(a) \\> 50 mg\u002FdL\n* current pregnancy or planned pregnancy during the study period\n* planned major operations\n* liver dysfunction\n* end-stage renal failure\n* other systemic conditions that might interfere with successful study participation\n* Plans to change drug (including hormonal) treatment in the upcoming 6 months\n* Use of another digital intervention for hypercholesterolemia\u002Fdyslipidemia in the past",{"count":665,"type":24},272,[27],"The goal of this clinical trial is to find out if lipodia, a digital health intervention, can help lower cholesterol levels and improve other health measures in adults with high cholesterol.\n\nThe main questions it aims to answer are:\n\n* Does lipodia, together with regular treatment, lower LDL cholesterol (bad cholesterol) better than regular treatment alone?\n* Does lipodia help improve other health outcomes, like how confident participants feel in managing their health?\n\nResearchers will compare two groups:\n\n* Intervention group: Participants use the lipodia intervention and continue their usual treatment.\n* Control group: Participants continue with their usual treatment only.\n\nParticipants will:\n\n* Fill out questionnaires online and visit a certified lab at the start of the study, after 3 months, and after 6 months\n* Have blood tests at each lab visit to check their cholesterol and other blood fat levels\n* Continue with their usual treatment (both groups) and use lipodia, a digital health app, for six months (intervention group only)",[669,32],"Hypercholesterolemia",[671,672],"LDL-C","digital intervention","2025-08-18",{"date":675,"type":48},"2025-08-22",{"date":677,"type":48},"2025-02-03",{"date":679,"type":24},"2026-01",{"name":681,"class":143},"Gaia AG"]